Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA Facility Self-Identification Pace Slow As Deadline Neared

Executive Summary

API, finished dosage form and other facilities in the generic drug supply chain must submit information to FDA by Dec. 3. As of Nov. 18, about one-third had complied, potentially affecting user fee amounts.


Related Content

GDUFA Facility Fees Will Be Significantly Higher Than Expected
GDUFA: Will Industry Self-Identification Push Lengthen The Backlog?
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
Generic Drug Facilities Guidance Details Who Self-Identifies, And Who Pays Fees
FDA Explains How Generic Firms Will Self-Identify Facilities Under New User Fee Program
Generic Facility Fee Unlikely To Be Charged Until A Few Months After GDUFA Implementation
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five
Establishment Fees Protect American Manufacturing, Mylan Argues In User Fee Proposal





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts